- Molecular NameMeclofenamic acid
- SynonymAcide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; Meclofenamate; Meclomen (free acid); Meclophenamic acid
- Weight296.153
- Drugbank_IDDB00939
- ACS_NO644-62-2
- Show 3D model
- LogP (experiment)6.0
- LogP (predicted, AB/LogP v2.0)5.64
- pka3.7
- LogD (pH=7, predicted)2.57
- Solubility (experiment)0.03 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.71
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors2
- No.of HBond Acceptors3
- No.of Rotatable Bonds3
- TPSA49.33
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug used for joint and muscular pain.
- Absorption_value100.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability65.1
- Protein binding99.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Meclofenamate is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamate) and at least six other less well characterized minor metabolites. Only this Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamate.
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe most frequently reported adverse reactions associated with meclofenamate sodium involve the gastrointestinal system and include diarrhea (10% to 33%), nausea with or without vomiting (11%), other gastrointestinal disorders (10%), and abdominal pain. Other reactions less frequently reported were pyrosis, flatulence, anorexia, constipation, stomatitis, and peptic ulcer. Edema, rash, urticaria, pruritus, headache, dizziness, tinnitus have also been reported.
- LD50 (rat)N/A
- LD50 (mouse)N/A